Major Histocompatibility Class II Pathway Is Not Required for the Development of Nonalcoholic Fatty Liver Disease in Mice

<table>Effect of 4-week CCl<sub>4</sub> treatment on GFAP staining in wild-type and MHCII<sup>Δ/Δ</sup> mice. Glial fibrillary acidic protein (GFAP; white arrows) was stained in red. Increased positive staining was observed in CCl<sub>4</sub>-treated MHCII<sup>Δ/Δ</sup> mice. Blue: DAPI staining.</table>

International Journal of Endocrinology

fig9

Figure 9

Figure 9: Major Histocompatibility Class II Pathway Is Not Required for the Development of Nonalcoholic Fatty Liver Disease in Mice 